Lasa Supergenerics Key Ratios
NSE: LASA | BSE: 540702
₹6.94
As on 26-Aug-2026IST
Market cap
₹35 Cr
Revenue (TTM)
₹6 Cr
P/E Ratio
--
P/B Ratio
0.8
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 1,029.55 | -93.87 | -95.17 | -63.55 | -48.98 |
| EBIT | 13.71 | -42.71 | -100.70 | -57.59 | -190.01 |
| Net Profit | 16.16 | -67.63 | -156.18 | -5.35 | -196.92 |
| EPS | 14.08 | 83.05 | 50.06 | 14.86 | -194.10 |
| Book Value | -- | -- | -18.27 | -20.96 | -15.97 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-24 | Mar-23 |
| EBIT-Margin
| -7.48 | 0.12 | -224.58 | -8.10 | -15.45 |
| Net Margin
| -18.03 | -8.13 | -253.90 | -20.81 | -29.39 |
| Return on equity
| -17.18 | -6.69 | -29.40 | -20.22 | -27.97 |
| Return on Capital
| -13.53 | -3.33 | -- | -13.23 | -23.94 |
| Return on Assets
| -12.36 | -5.03 | -19.73 | -13.81 | -20.71 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.23 | 0.18 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
--
|
-13.23
|
-23.94
|
-3.41
|
17.14
|
|
Peer Median
|
--
|
16.46
|
15.49
|
17.37
|
17.62
|
ROE
-29.40
Lower than Peers by 39.34
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
-29.40
|
-20.22
|
-27.97
|
-3.37
|
15.17
|
|
Peer Median
|
9.94
|
13.87
|
14.72
|
15.70
|
18.36
|
ROA
-19.73
Lower than Peers by 26.99
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
-19.73
|
-13.81
|
-20.71
|
-2.56
|
10.43
|
|
Peer Median
|
7.26
|
8.04
|
7.19
|
9.43
|
9.43
|
EBIT Margin
-224.58
Lower than Peers by 234.12
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
-224.58
|
-8.10
|
-15.45
|
1.10
|
15.51
|
|
Peer Median
|
9.55
|
10.05
|
10.28
|
13.90
|
17.27
|
Net Margin
-253.90
Lower than Peers by 262.53
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
-253.90
|
-20.81
|
-29.39
|
-3.88
|
11.25
|
|
Peer Median
|
8.64
|
9.11
|
6.78
|
10.91
|
12.99
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
0.00
|
-10.60
|
-19.45
|
6.69
|
19.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-95.17
Lower than Peers by 101.41
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
-95.17
|
-19.47
|
-5.51
|
-32.24
|
21.00
|
|
Peer Median
|
6.24
|
7.17
|
10.56
|
12.63
|
15.47
|
EBIT Growth
-100.70
Lower than Peers by 100.64
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
-100.70
|
57.79
|
-1,428.98
|
-95.20
|
148.53
|
|
Peer Median
|
-0.06
|
12.05
|
6.17
|
-2.90
|
51.73
|
Net Profit Growth
-156.18
Lower than Peers by 163.76
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
-156.18
|
43.73
|
-624.41
|
-123.41
|
527.76
|
|
Peer Median
|
7.58
|
22.15
|
27.97
|
-14.10
|
44.15
|
EPS Growth
50.06
Higher than Peers by 47.87
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
50.06
|
43.73
|
-624.42
|
-119.00
|
527.75
|
|
Peer Median
|
2.18
|
8.80
|
--
|
-3.68
|
38.52
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
--
|
-18.27
|
-25.08
|
-0.65
|
12.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
--
|
0.23
|
0.18
|
0.13
|
0.12
|
|
Peer Median
|
0.02
|
0.03
|
0.05
|
0.14
|
0.23
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.62
Lower than Peers by 1.82
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
0.62
|
0.78
|
0.92
|
1.48
|
1.59
|
|
Peer Median
|
2.45
|
2.20
|
1.93
|
1.82
|
1.75
|
Quick Ratio
0.51
Lower than Peers by 1.20
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
0.51
|
0.39
|
0.59
|
1.22
|
1.16
|
|
Peer Median
|
1.72
|
1.72
|
1.59
|
1.30
|
1.04
|
Interest Coverage
-30.16
Lower than Peers by 39.87
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
-30.16
|
-8.60
|
-9.09
|
-93.74
|
15.28
|
|
Peer Median
|
9.71
|
12.28
|
12.45
|
16.98
|
15.07
|
Operating Efficiency
Debtors to sales
0.65
Lower than Peers by 26.27
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
0.65
|
3.44
|
1.91
|
13.53
|
7.30
|
|
Peer Median
|
26.91
|
26.23
|
23.97
|
24.57
|
20.26
|
Asset Turnover
0.08
Lower than Peers by 0.60
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
0.08
|
0.66
|
0.69
|
0.66
|
0.93
|
|
Peer Median
|
0.67
|
0.74
|
0.88
|
0.82
|
0.79
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
--
|
10.61
|
29.63
|
44.35
|
31.94
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
--
|
57.63
|
35.78
|
38.27
|
39.28
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
--
|
56.97
|
45.30
|
59.24
|
75.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
--
|
11.27
|
20.11
|
23.39
|
-4.24
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-2.18
Lower than Peers by 57.97
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
-2.18
|
--
|
--
|
--
|
10.70
|
|
Peer Median
|
55.79
|
39.17
|
40.74
|
25.97
|
33.71
|
Price / Book Value
0.76
Lower than Peers by 3.72
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
0.76
|
1.14
|
0.78
|
1.32
|
1.53
|
|
Peer Median
|
4.48
|
3.61
|
3.87
|
2.79
|
4.36
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
--
|
--
|
--
|
0.60
|
0.42
|
|
Peer Median
|
0.14
|
0.19
|
0.20
|
0.65
|
0.28
|
EV/EBITDA
-5.45
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
-5.45
|
56.20
|
-23.51
|
13.00
|
5.46
|
|
Peer Median
|
--
|
28.79
|
25.41
|
15.07
|
23.32
|
Market Cap
35
Lower than Peers by 5,426
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Lasa Supergenerics
|
35
|
110
|
93
|
209
|
244
|
|
Peer Median
|
5,461
|
3,944
|
2,959
|
3,742
|
6,050
|